SCHEDULE: Lincoln Alternative Strategies Discloses 9.9% Stake in Purple Biotech

Lincoln Alternative Strategies LLC has reported a 9.9% beneficial ownership stake in Purple Biotech Ltd., holding 605,000 American Depositary Shares.

Summary

• Lincoln Alternative Strategies LLC has filed a Schedule 13G, disclosing beneficial ownership of 605,000 American Depositary Shares (ADS) of Purple Biotech Ltd.
• This ownership represents 9.9% of Purple Biotech Ltd.'s outstanding class of securities.
• The beneficial ownership percentage is calculated based on 6,085,450 shares of the Issuer's common stock issued and outstanding as of September 4, 2025.
• Lincoln Alternative Strategies LLC holds sole voting power and sole dispositive power over all 605,000 shares.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant institutional investor has disclosed a substantial stake, indicating confidence in the company. The passive nature of the investment (not for control) is also a positive signal.

Positives

• A significant institutional investor, Lincoln Alternative Strategies LLC, has taken a substantial 9.9% stake in Purple Biotech Ltd., indicating confidence in the company's prospects.
• The filing explicitly states that the stake was not acquired for the purpose of changing or influencing control, suggesting a passive investment strategy focused on long-term value.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Purple Biotech Ltd. or Lincoln Alternative Strategies LLC regarding future performance or strategic direction.

Industry Context

The disclosure of a significant institutional stake in a biotech company like Purple Biotech Ltd. can signal increased investor interest in the sector, potentially driven by specific company developments or broader market trends in biotechnology and pharmaceuticals. Such investments often reflect a belief in the long-term growth potential of the company's pipeline or market position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further institutional interest, which could positively influence share price.
• Company Management: A large, passive institutional investor can provide stability and long-term support, but also implies increased scrutiny on performance.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Lincoln Alternative Strategies LLC is a positive signal, a Schedule 13G filing alone does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. It primarily indicates institutional interest and a passive investment approach. Investors should 'hold' and await further financial reports or strategic updates from Purple Biotech Ltd. to make a more informed decision, while acknowledging the positive signal of institutional confidence.

Keywords

Purple Biotech Ltd., Lincoln Alternative Strategies LLC, Schedule 13G, Beneficial Ownership, American Depositary Shares, ADS, Biotech, Institutional Investment, Equity Stake